Literature DB >> 9322978

Counterregulatory actions of angiotensin-(1-7).

C M Ferrario1, M C Chappell, E A Tallant, K B Brosnihan, D I Diz.   

Abstract

Angiotensin (Ang)-(1-7) is a bioactive component of the renin-angiotensin system that is formed endogenously from either Ang I or Ang II. The first actions described for Ang-(1-7) indicated that the peptide mimicked some of the effects of Ang II, including the release of prostanoids and vasopressin. However, Ang-(1-7) is devoid of vasoconstrictor, central pressor, or thirst-stimulating actions. In fact, new findings reveal depressor, vasodilator, and antihypertensive actions that may be more apparent in hypertensive animals or humans. Thus, the accumulating evidence suggests that Ang-(1-7) may oppose the actions of Ang II either directly or by stimulation of prostaglandins and nitric oxide. These observations are significant because they may explain the effective antihypertensive action of converting enzyme inhibitors in a variety of non-renin-dependent models of experimental and genetic hypertension as well as most forms of human hypertension. In this context, studies in humans and animals showed that the antihypertensive action of converting enzyme inhibitors correlated with increases in plasma levels of Ang-(1-7). In this review, we summarize our knowledge of the mechanisms accounting for the counterregulatory actions of Ang-(1-7) and elaborate on the emerging concept that Ang-(1-7) functions as an antihypertensive peptide within the cascade of the renin-angiotensin system.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9322978     DOI: 10.1161/01.hyp.30.3.535

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  127 in total

1.  Vasoconstriction is determined by interstitial rather than circulating angiotensin II.

Authors:  Martin P Schuijt; René de Vries; Pramod R Saxena; Maarten A D H Schalekamp; A H Jan Danser
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

2.  Angiotensin-(1-7) attenuates angiotensin II-induced cardiac remodeling associated with upregulation of dual-specificity phosphatase 1.

Authors:  Latronya T McCollum; Patricia E Gallagher; E Ann Tallant
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-12-02       Impact factor: 4.733

3.  Advances in the renin angiotensin system focus on angiotensin-converting enzyme 2 and angiotensin-(1-7).

Authors:  Carlos M Ferrario; Sarfaraz Ahmad; Janae Joyner; Jasmina Varagic
Journal:  Adv Pharmacol       Date:  2010

Review 4.  Angiotensin-converting enzymes and drug discovery in cardiovascular diseases.

Authors:  Lijun Shi; Caiping Mao; Zhice Xu; Lubo Zhang
Journal:  Drug Discov Today       Date:  2010-02-17       Impact factor: 7.851

Review 5.  Proximal nephron.

Authors:  Jia L Zhuo; Xiao C Li
Journal:  Compr Physiol       Date:  2013-07       Impact factor: 9.090

6.  Diminazene aceturate enhances angiotensin-converting enzyme 2 activity and attenuates ischemia-induced cardiac pathophysiology.

Authors:  Yanfei Qi; Juan Zhang; Colleen T Cole-Jeffrey; Vinayak Shenoy; Andrew Espejo; Mina Hanna; Chunjuan Song; Carl J Pepine; Michael J Katovich; Mohan K Raizada
Journal:  Hypertension       Date:  2013-08-19       Impact factor: 10.190

Review 7.  An evolving story of angiotensin-II-forming pathways in rodents and humans.

Authors:  Carlos Maria Ferrario; Sarfaraz Ahmad; Sayaka Nagata; Stephen W Simington; Jasmina Varagic; Neal Kon; Louis Joseph Dell'italia
Journal:  Clin Sci (Lond)       Date:  2014-04       Impact factor: 6.124

8.  Oxidative stress-mediated effects of angiotensin II in the cardiovascular system.

Authors:  Hairuo Wen; Judith K Gwathmey; Lai-Hua Xie
Journal:  World J Hypertens       Date:  2012-08-23

9.  Effects of decreased renal cortical expression of G protein-coupled receptor kinase 4 and angiotensin type 1 receptors in rats.

Authors:  Junichi Yatabe; Hironobu Sanada; Sanae Midorikawa; Shigeatsu Hashimoto; Tsuyoshi Watanabe; Peter M Andrews; Ines Armando; Xiaoyan Wang; Robin A Felder; Pedro A Jose
Journal:  Hypertens Res       Date:  2008-07       Impact factor: 3.872

Review 10.  Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control.

Authors:  Carlos M Ferrario
Journal:  Life Sci       Date:  2009-12-01       Impact factor: 5.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.